1. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Issue 7 (July 2021) Authors: Powles, Thomas; Csőszi, Tibor; Özgüroğlu, Mustafa; Matsubara, Nobuaki; Géczi, Lajos; Cheng, Susanna Y-S; Fradet, Yves; Oudard, Stephane; Vulsteke, Christof; Morales Barrera, Rafael; Fléchon, Aude; Gunduz, Seyda; Loriot, Yohann; Rodriguez-Vida, Alejo; Mamtani, Ronac; Yu, Evan Y; Nam, Kijoeng; Imai... Journal: Lancet oncology Issue: Volume 22:Issue 7(2021) Page Start: 931 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗